Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04522323 · ClinicalTrials.gov registry record · Phase 1

A Study to Evaluate MEDI5752 and Axitinib in Subjects With Advanced Renal Cell Carcinoma

A Phase 1 study of Advanced Renal Cell Carcinoma, sponsored by MedImmune.

Active
Registry status
Phase 1
Development phase
67
Enrollment target
20
Study locations

NCT04522323: Active Phase 1 study of Advanced Renal Cell Carcinoma, sponsored by MedImmune.

NCT04522323 is a Phase 1 study of Advanced Renal Cell Carcinoma that is active but no longer recruiting, run by MedImmune. The registered enrollment target is 67 participants, below the 88-participant average among 12 other Advanced Renal Cell Carcinoma trials with a reported enrollment target (24% lower). The trial reports 20 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04522323, a Phase 1 study of Advanced Renal Cell Carcinoma, is active but no longer recruiting, sponsored by MedImmune.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
67 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to evaluate MEDI5752 in combination with Lenvatinib (or Axitinib), in subjects with advanced renal cell carcinoma.

Primary Outcome

The primary safety endpoint is as assessed by the number of subjects with adverse events and serious adverse events (SAEs) graded per NCI CTCAE v5.0.

Conditions Studied

Advanced Renal Cell Carcinoma

Interventions

  • DRUG Lenvatinib
  • DRUG Axitinib
  • BIOLOGICAL MEDI5752

Study Locations (20)

Other

  • Research Site - Frankston
  • Research Site - Waratah
  • Research Site - Villejuif
  • Research Site - Barcelona
  • Research Site - Barcelona
  • Research Site - Barcelona
  • Research Site - Barcelona
  • Research Site - Córdoba
  • Research Site - Madrid
  • Research Site - Madrid
  • Research Site - Sabadell
  • Research Site - Seville
  • Research Site - Valencia

District of Columbia

  • Research Site - Washington D.C.

Florida

  • Research Site - Fort Myers

Missouri

  • Research Site - St Louis

New York

  • Research Site - New York

Ohio

  • Research Site - Cleveland

Pennsylvania

  • Research Site - Hershey

Tennessee

  • Research Site - Nashville

Trial Details

FieldValue
Enrollment Target 67 participants
Start Date 2020-08-05
Est. Completion 2025-09-26
Phase Phase 1
MedImmune

210 total trials

What the registry record for NCT04522323 still lists

NCT04522323 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 67 participants, a relatively small participant target, below the 88-participant average among 12 other Advanced Renal Cell Carcinoma trials with a reported enrollment target (24% lower).

The record links to 1 condition, with Advanced Renal Cell Carcinoma appearing as the primary indexed condition, and to 3 interventions - of which Lenvatinib is the first listed.

NCT04522323 names 20 study sites across 8 states, led by Other, District of Columbia, Florida.

Frequently Asked Questions

What is clinical trial NCT04522323 about?

NCT04522323 is a clinical study titled "A Study to Evaluate MEDI5752 and Axitinib in Subjects With Advanced Renal Cell Carcinoma". The purpose of this study is to evaluate MEDI5752 in combination with Lenvatinib (or Axitinib), in subjects with advanced renal cell carcinoma.

What is the current status of trial NCT04522323?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 67 participants. The study started on 2020-08-05. Estimated completion is 2025-09-26.

What conditions does trial NCT04522323 study?

This clinical trial studies the following conditions: Advanced Renal Cell Carcinoma.

What interventions are being tested in trial NCT04522323?

The interventions under investigation include: Lenvatinib (DRUG), Axitinib (DRUG), MEDI5752 (BIOLOGICAL).

Who is sponsoring clinical trial NCT04522323?

This trial is sponsored by MedImmune, which has 210 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04522323 being conducted?

This trial has 20 study locations across District of Columbia, Florida, Missouri, New York, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Advanced Renal Cell Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04522323's enrollment target sits among peer trials

67 7th of 12 higher than 6 of 12 other Advanced Renal Cell Carcinoma trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Advanced Renal Cell Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03213002 · 67 participants · Phase 1

    Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM

  • NCT04115163 · 67 participants · Phase 2

    Biologically Optimized Infusion Schedule of Gemcitabine and Nab-Paclitaxel for the Treatment of Metastatic Pancreatic Cancer

  • NCT04315324 · 67 participants · Phase 1

    Study to Test OBI-3424 in Patients With T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LBL)

  • NCT04532424 · 67 participants · NA

    Transcranial Magnetic Stimulation for Restricted and Repetitive Behavior in ASD

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT04522323, the US trial registry maintained by the National Library of Medicine. NCT04522323 (small enrollment · wide site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.